{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-24-000039","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.677187+00:00","generated_at":"2026-06-04T13:22:02.551799+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acumen reports $306M cash, runway into H1 2027; plans Phase 2-only ALTITUDE-AD study","bullets":["Cash, cash equivalents and marketable securities ~$306M as of Dec 31, 2023 (preliminary, unaudited).","Company expects cash to fund operations into first half of 2027.","Anticipates amending ALTITUDE-AD Phase 2/3 protocol to a standalone Phase 2 study.","Updated corporate presentation posted on investor website on March 19, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-24-000039","json":"https://secwatch.observer/filing/0001576885-24-000039.json","markdown":"https://secwatch.observer/filing/0001576885-24-000039.md","text":"https://secwatch.observer/filing/0001576885-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000039/0001576885-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000039/abos-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:22:02.551799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}